ENMD-2076
2076-CL-003
Phase 1 small_molecule completed
Quick answer
ENMD-2076 for Relapsed or Refractory Hematological Malignancies is a Phase 1 program (small_molecule) at CASI Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CASI Pharmaceuticals
- Indication
- Relapsed or Refractory Hematological Malignancies
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed